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Atopic dermatitis (AD) is a chronic inflammatory skin disease
characterized by a broad spectrum of symptoms including
itch, skin pain, mental health problems and difficulties in
sleeping.1 AD may substantially affect patients’ health-related
quality of life (HRQoL) and ability to work. Most available
studies concerned with HRQoL in patients with AD are limited
to one country, and little is known about the cross-country
variation in HRQoL in this patient population. As clinical and
quality-of-life data are often specific to the country of interest,
their transferability to other jurisdictions remains uncertain.2
In this issue of the BJD, Andersen et al. present the results of
a large online survey about self-reported severity and HRQoL
in 1232 patients with AD from four countries (France, Ger-
many, the U.K. and the U.S.A.).3 The sociodemographic and
clinical characteristics of the patients were well matched
between the European and U.S. patient populations. However,
age at diagnosis and the proportion of smokers were higher,
whereas the percentage of obese patients was lower in Europe.
A wide range of validated outcome measures have been used,
including the AD-specific Patient Oriented Eczema Measure, the
skin-specific Dermatology Life Quality Index (DLQI) and the
generic instruments EuroQol EQ-5D-5L and EQ visual analogue
scale (VAS). Patients assessed their disease severity using the
Patient-Oriented Scoring of AD (PO-SCORAD).
The study by Andersen et al. is the first in the literature to
estimate EQ-5D-5L index and EQ VAS scores for PO-SCORAD
score bands.3 EQ VAS scores indicated worse HRQoL in patients
with higher self-reported disease severity. On a scale ranging
from 0 (the worst health you can imagine) to 100 (the best
health you can imagine), mean EQ VAS scores of patients with
mild, moderate, severe 1, severe 2 and severe 3+ AD were 754,
664, 610, 581 and 497, respectively. In contrast, other stud-
ies reported mean EQ VAS scores of 724 in psoriasis, 680 in
pemphigus and 568 in hidradenitis suppurativa.4–6
For all severity groups of patients, higher DLQI and lower
EQ-5D-5L index were reported in Europe than in the U.S.A.,
but no statistically significant difference was revealed. There-
fore, the results suggest that HRQoL impairment is similar and
consistent between the European and U.S. patient populations.
A major strength of the study is that it includes patients from
four countries, which contributes to the generalizability of the
findings. Future research comparing HRQoL and clinical out-
comes of patients with AD from different countries and
regions, particularly from those with different sociocultural
backgrounds, may provide evidence of wider generalizability.
Considering the expanding arena of HRQoL instruments avail-
able for patients with AD, another future research direction
could be to test the generalizability of other skin-specific or
disease-specific patient-reported outcome measures for AD,
such as DLQI-Relevant, Skindex, Quality of Life Index for Ato-
pic Dermatitis, 5-D Itch Scale or ItchyQol.7–9
F. Rencz iD 1,2
1Department of Health Economics, Corvinus University of Budapest, 8 F}ovam
ter, H-1093 Budapest, Hungary; and 2Hungarian Academy of Sciences,




1 Weidinger S, Novak N. Atopic dermatitis. Lancet 2016; 387:1109–22.
2 Oppong R, Jowett S, Roberts TE. Economic evaluation alongside
multinational studies: a systematic review of empirical studies. PLOS
ONE 2015; 10:e0131949.
3 Andersen L, Nyeland ME, Nyberg F. Higher self-reported severity of
atopic dermatitis in adults is associated with poorer self-reported
health-related quality of life in France, Germany, the U.K. and the
U.S.A. Br J Dermatol 2019; https://doi.org/10.1111/bjd.18451.
[Epub ahead of print]
4 Matusiak L, Bieniek A, Szepietowski JC. Psychophysical aspects of
hidradenitis suppurativa. Acta Derm Venereol 2010; 90:264–8.
5 Poor AK, Rencz F, Brodszky V et al. Measurement properties of the
EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. Qual Life
Res 2017; 26:3409–19.
6 Tamasi B, Brodszky V, Pentek M et al. Validity of the EQ-5D in
patients with pemphigus vulgaris and pemphigus foliaceus. Br J Der-
matol 2019; 180:802–9.
7 Vakharia PP, Cella D, Silverberg JI. Patient-reported outcomes and
quality of life measures in atopic dermatitis. Clin Dermatol 2018;
36:616–30.
8 Rencz F, Gulacsi L, Pentek M et al. Proposal of a new scoring for-
mula for the Dermatology Life Quality Index in psoriasis. Br J Derma-
tol 2018; 179:1102–8.
9 Rencz F, Gulacsi L, Pentek M et al. DLQI-R scoring improves the dis-
criminatory power of the Dermatology Life Quality Index in
patients with psoriasis, pemphigus and morphoea. Br J Dermatol
2019; DOI: 10.1111/bjd.18435.
Conflicts of interest: none to declare.
© 2019 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists
British Journal of Dermatology (2019) 1
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
